Psychiatry

Back to articles

Varenicline demonstrates safety, efficacy in smokers with depression

KEY POINT

In adult smokers with a current or recent history of treatment for stable major depression, varenicline (Chantix—Pfizer) was more effective than placebo for smoking cessation and was not associated with increased rates of anxiety, depressed mood, or suicidal ideation or behavior over a 52-week period.